UK Markets closed
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • FTSE 250

    19,835.95
    +146.93 (+0.75%)
     
  • AIM

    956.64
    +9.47 (+1.00%)
     
  • GBP/EUR

    1.1822
    +0.0040 (+0.34%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • BTC-GBP

    23,528.81
    +31.87 (+0.14%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • DOW

    31,261.90
    +8.77 (+0.03%)
     
  • CRUDE OIL

    110.35
    +0.46 (+0.42%)
     
  • GOLD FUTURES

    1,845.10
    +3.90 (+0.21%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • DAX

    13,981.91
    +99.61 (+0.72%)
     
  • CAC 40

    6,285.24
    +12.53 (+0.20%)
     

Grifols shares soar as plasma collection reaches pre-pandemic levels

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
The logo of the Spanish pharmaceuticals company Grifols is pictured on their headquarters' building in Sant Cugat del Valles
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MADRID (Reuters) - Spanish pharmaceuticals company Grifols' shares soared on Friday as the company reported the volumes of blood plasma it collected reached pre-pandemic levels in the first quarter.

The shares were up 7.3% in mid-morning trading on Friday, while the blue chip IBEX-35 index was down 0.5%.

Grifols' collection of the blood plasma it uses to make haematology medicines, collapsed during the COVID-19 pandemic when its collection centres around the world were closed, hitting its net profit, which fell 70% in 2021.

As a result Grifols lost around 50% of its market value since the COVID-19 pandemic started in 2020 when its shares were trading at record levels.

Grifols said on Friday plasma collections in the first quarter grew 16% from the same period in 2021, and 9% from the previous quarter, while revenue grew by mid-to-high single digit.

"The primary engines of growth were recent openings and recently-acquired plasma centres; larger plasma volumes from regular centres; and the achievement of greater efficiencies," the company said in a statement, adding the efficiencies are likely to further boost plasma collection volumes.

Grifols closed 2021 with a debt of 5.8 billion euros ($6.1 billion), the equivalent of five times its earnings before interest, taxes, depreciation and amortization. The company said it intends to cut its debt to a ratio of 4 through cost-cutting, lower capital expenditure, no cash dividend and refraining from acquisitions.

($1 = 0.9455 euros)

(Reporting by Emma Pinedo, editing by Inti Landauro and Emelia Sithole-Matarise)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting